CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024(Unaudited, in thousands, except ASP data) Revenue $17,244$12,507 $49,944$41,986 Gross margin 58.4% 55.8% 59.3% 58.7%Operating expenses $13,175$11,644 $38,688$34,888 Operatin ...